What are the latest trends shaping the biopharma industry in China? The exclusive Building Bridges to Innovation report by McKinsey & Co. was commissioned for the 5th BioCentury-BayHelix China Healthcare Summit (Nov. 13-14, 2018, Shanghai).
Will quality and reimbursement reforms create a “year of reckoning” for mature brands in China?
How fast is market access improving in China for innovative products?
Has the war for talent in China reached a boiling point?
Can local biopharma innovation compete with multinational products in China?
How will digitization improve physician and patient engagement in China?
Plus: The third edition of McKinsey’s China Drug Innovation Index (CDII)
Download the Whitepaper
To download Building Bridges to Innovation 2018, please click the DOWNLOAD link below.
By requesting this White Paper, you hereby Consent to and Agree your personal data will be processed by BioCentury Inc. and McKinsey & Co., the sponsor of the White Paper, in connection with the specific uses set forth below.
Also, you agree that BioCentury may use your information to send you notices about BioCentury publications, products, conferences and services that are of interest to life sciences professionals and investors like yourself, along with notices about conferences and offers from other companies we believe will be of interest to you. Your information is not otherwise shared with any other third parties for marketing purposes.